Prognostic value of preoperative fibrinogen, neutrophil-to-lymphocyte ratio, serum alpha-fetoprotein, and prealbumin for patients with primary liver cancer undergoing transarterial chemoembolization

Figure 1 Comparison of blood test results between the two groups. A: Hemoglobin; B: White blood cell (WBC); C: Neutrophils; D: Lymphocytes; E: Platelet (PLT); F: Monocytes; G: Red cell distribution width (RDW); H: Mean platelet volume (MPV).

Figure 2 Comparison of alpha-fetoprotein before transarterial chemoembolization between the two groups. ^cP < 0.001; AFP: Alpha-fetoprotein.

Figure 3 Comparison of liver function indicators between the two groups. A: Total Bilirubin; B: Alanine aminotransferase; C: Aspartate aminotransferase; D: Alkaline phosphatase; E: Prealbumin; F: Albumin; G: Gamma-glutamyl transferase. ^aP < 0.05; ^bP < 0.01; ALB: Albumin; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; PA: Prealbumin; TB: Total bilirubin.

Figure 4 Prognostic value of preoperative biomarkers in the treatment of primary liver cancer. AUC: Area under the curve; ROC: Receiver operating characteristic.